Skip to main content
Equibles
NRXS logo

NRXS · Neuraxis, INC · Webcasts, Transcripts & Audio

Track NRXS — free

Use NRXS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRXS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.83 +0.05 (+0.74%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$94.94M
Shares
12.56M
Volume · Oct 7 66.05K Avg daily vol (3M) 106.03K

Neuraxis, INC Webcasts

Earnings calls, investor updates, investor days and conferences for Neuraxis, INC (NRXS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼19.7% $646,635 −$2.12M '24 Q1 24-04-09 ▼5.3% $611,500 −$2.92M '24 Q2 24-08-09 ▲39.6% $666,625 −$1.76M '24 Q3 24-11-12 ▲21.7% $811,414 −$2.12M '25 Q3 25-11-11 ▲27.2% $968,127 −$1.71M '25 Q4 26-03-19 ▲79.5% $1.61M −$1.76M '26 Q1 26-05-12 LATEST ▲115.7% $1.93M −$2.09M '26 Q2 26-08-11
Conference
Investor event
2026-09-29
Neuraxis, INC (NRXS) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-11
Neuraxis, INC (NRXS) Q2 2026 Earnings Call Transcript
Confident tone Insurance coverage expansion Operating expense leverage and path to profitability Liquidity and capital management
Revenue
$1.93M
▲ 115.7% YoY
Diluted EPS
$-0.19
Gross margin
85.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Neuraxis, INC (NRXS) Q1 2026 Earnings Call Transcript
Positive tone Revenue growth and proof of concept Payer coverage and insurance access Category 1 CPT code and reimbursement
Revenue
$1.61M
▲ 79.5% YoY
Diluted EPS
$-0.18
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Neuraxis, INC (NRXS) Q4 2025 Earnings Call Transcript
Confident tone Insurance coverage / payer policy expansion PENFS / IB STEM technology and product Pediatric / children's hospital adoption
Revenue
$968,127*
▲ 27.2% YoY
Gross margin
85.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-11
Neuraxis, INC (NRXS) Q3 2025 Earnings Call Transcript
Positive tone RED Product Ramp Challenges Category 1 CPT Code Effective 01/01/2026 Adult IV Stem Indication Expansion and Risks
Revenue
$811,414
▲ 21.7% YoY
Diluted EPS
$-0.24
Gross margin
83.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-12
Neuraxis, INC (NRXS) Q3 2024 Earnings Call Transcript
Confident tone RED Product / Rectal Expulsion Device Insurance Coverage Expansion Academic Society Guidelines (NASPGHAN)
Revenue
$666,625
▲ 39.6% YoY
Diluted EPS
$-0.25
Gross margin
85.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Neuraxis, INC (NRXS) Q2 2024 Earnings Call Transcript
Confident tone IB-Stim Commercialization Insurance Coverage Expansion RED Product Launch
Revenue
$611,500
▼ 5.3% YoY
Diluted EPS
$-0.42
Gross margin
88.0%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-09
Neuraxis, INC (NRXS) Q1 2024 Earnings Call Transcript
Confident tone Insurance coverage expansion Patient demand and underlying business strength RED device development and FDA submission
Revenue
$646,635
▼ 19.7% YoY
Diluted EPS
$-0.32
Gross margin
88.4%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 webcasts
Key facts CIK 1933567 CUSIP 64134X201 13F (30d) 1 filings 1 filers Visit website Investor relations